A method for preparing crystalline valrubicin
Through the combined dissolution and washing method of ether and alkane solvents, high stability of urubicin rod-shaped crystals were prepared, which solved the problem of poor stability of urubicin in the prior art, and achieved a simple preparation process and high efficiency. Removal effect.
Patent Information
- Application Number
- CN201810183313.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2018-03-06
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2038-03-06
AI Technical Summary
The prior art has failed to effectively prepare the crystal form of verubibin crystal with good stability, resulting in poor stability in storage and transportation, and it is difficult to control the dissolution and moisture index.
The crude product of verubicin was dissolved with an ether solvent, and the mixture of small molecule ethers and alkanes was added to stir at low speed, then filtered and washed with alkanes, and then dried in vacuo to obtain rod-like crystals.
The stable crystal form preparation of verubicin is achieved, which simplifies operation, improves the removal effect, product stability and storage and transportation convenience, and complies with the pharmacopoeia standards.
Smart Images

Figure CN108530502B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical chemical crystallization, and particularly relates to a method for preparing crystalline valrubicin. Background Art
[0002] Valrubicin was originally developed by Anthra Pharmaceuticals in the United States and was first launched in the United States in 2009. It is mainly used to treat bladder cancer in situ. Its chemical name is (2S-cis)-2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetic acid)amino]-α-L-lyxopyranyl]-oxy]-2-naphthyl]-2-oxoethyl pentanoate, molecular formula: C 34 H 36 F3NO 13 , molecular weight: 723.65, structural formula is as follows:
[0003]
[0004] Valrubicin is an anthracycline drug, and its main function is to interfere with the division and recombination of normal DNA. It may affect various biological functions of cells, mainly interfering with nucleic acid metabolism. This product easily penetrates into cells, inhibits nucleosides from forming nucleic acids, thereby causing a large amount of chromosome damage and stopping the cell cycle at the G2 phase. It is clinically administered by intravesical instillation for the treatment of bladder cancer, with obvious effects and good tolerance.
[0005] Patents WO2003057687A1, WO03057896A1, CN103694291B, and the document Organic Pr℃ess Research & Development 2005, 9, 818-821 all describe how to prepare valrubicin, but none of them mention the crystallization method. The product is only obtained by concentrating to dryness during post-treatment. Only the document SYNTHETIC COMMUNICATIONS, 29(20), 3581-3586 (1999) mentions that the product is crystallized from a chloroform / n-hexane system. However, we repeated the process according to the document and found that the obtained product is an amorphous powder without a crystalline form. In addition, experiments have shown that the crystallization methods mentioned in the literature have basically no impurity removal effect. They only convert the product from a solution into a red solid powder without a crystalline form. Generally, the stability of amorphous solids is relatively poor, which is not conducive to the control of indicators such as residual solvent and moisture, and is also not conducive to storage and transportation. Therefore, it is urgent to find a crystallization method that can both remove impurities and obtain stable crystal forms. Summary of the invention
[0006] To make up for the deficiencies of the prior art, the present invention provides a method for preparing crystalline valrubicin, which is simple to operate and has an obvious impurity removal effect. The prepared valrubicin has better stability than amorphous valrubicin and is easy to store and transport.
[0007] The present invention is achieved through the following technical solutions:
[0008] A method for preparing crystalline valrubicin, which is special in that:
[0009] The following steps are involved:
[0010] (1) Take crude valrubicin and dissolve it in an ether solvent;
[0011] (2) adding a mixed solvent of small molecular ethers and alkanes to the dissolved crude product, and then stirring at a low speed for 0.5-10 hours to crystallize; the volume of the mixed solvent is 1-15 times the volume of the solvent;
[0012] (3) Filtering, washing with an alkane solvent, and vacuum drying at 0-60° C. for 1-50 h to obtain rod-shaped crystalline valrubicin.
[0013] In the method for preparing crystalline valrubicin of the present invention, the ratio of the crude valrubicin to the ether solvent in step (1) is 1 g: (1-15) ml.
[0014] Furthermore, the ether solvent in step (1) is one or more of diethyl ether, isopropyl ether, propyl ether, butyl ether, isobutyl ether, methyl tert-butyl ether, ethyl tert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
[0015] In step (2), the volume ratio of the small molecule ether solvent to the alkane solvent is 1:(0.1-20).
[0016] The small molecular weight ethers in step (2) include one or more of diethyl ether, tert-butyl methyl ether, dibutyl ether, isobutyl ether, isopropyl ether, tetrahydrofuran, and 1,4-dioxane.
[0017] The alkane solvent in step (2) and step (3) is one or more of n-hexane, cyclohexane, n-pentane, isopentane, cyclopentane, n-heptane and petroleum ether.
[0018] The volume of the alkane solvent used in step (3) is 1-5 times the volume of the melting medium.
[0019] The method for preparing the crystal form of valrubicin of the present invention is that the prepared valrubicin is in a rod-shaped crystal form.
[0020] The method for preparing the crystalline form of valrubicin of the present invention comprises an X-ray diffraction spectrum of the prepared crystalline form of valrubicin having characteristic peaks at the following 2θ angles: 6.7±0.2°, 7.4±0.2°, 9.9±0.2°, 16.8±0.2°, 17.2±0.2°, 20.9±0.2°, and 22.8±0.2°.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] (1) The present invention prepares a crystalline form of valrubicin, which is the first reported at home and abroad. The crystalline valrubicin has good stability, is easy to store and transport, and indicators such as residual solubility and moisture content are easy to control.
[0023] (2) The method for preparing the crystal form is simple to operate, has a short cycle, good stability, and is effective in removing impurities. All indicators of the obtained product can meet the pharmacopoeia standards.
[0024] (3) The solvents used in the present invention are all commonly used reagents, which are easy to handle, produce less waste, have little impact on the environment, and are suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Attached Figure 1 is the XRPD spectrum of the product of Example 1 of the present invention;
[0026] Attached Figure 2 This is a photo of the product of Example 1 of the present invention under a microscope. DETAILED DESCRIPTION
[0027] The present invention is further described in detail below in conjunction with specific implementation methods to help those skilled in the art have a more complete, accurate and in-depth understanding of the inventive concept and technical solution of the present invention. The protection scope of the present invention includes but is not limited to the following embodiments. Any modifications made to the details and forms of the technical solution of the present invention without departing from the spirit and scope of the present application shall fall within the protection scope of the present invention.
[0028] Example 1
[0029] Take 20g of valrubicin, dissolve it in 60 mL of tetrahydrofuran, slowly add 180mL of mixed solvent (20mL of ether + 160mL of n-hexane), stir at low speed for 3h, and crystallize. Filter, and wash the filter cake with 60mL of n-hexane. The filter cake is vacuum dried at 30°C for 30h to obtain 18.6g of rod-shaped valrubicin with a yield of 93%. The product was tested by X-ray powder diffraction (XRPD), and its XRPD spectrum is attached. Figure 1 , the appearance under the microscope is as shown in the attached Figure 2 shown.
[0030] X-ray powder diffraction (XRPD) detection conditions and methods: The instrument is: D / max 2500 / PC rotating target X-ray diffractometer, Rigaku Corporation, Japan; test conditions: tube voltage: 40 kV, tube current: 100 mA, Cu target, graphite bent monochromator, continuous scanning, scanning step: 0.02°, scanning range: 3-40° (2θ), slit system: DS=SS=1°, RS=0.3mm.
[0031] Example 2
[0032] Take 20g of crude valrubicin, dissolve it in 80mL of 1,4-dioxane, slowly add 240mL of mixed solvent (30mL of ether + 210mL of n-hexane), stir at low speed for 3h, and crystallize. Filter, wash the filter cake with 100mL of n-hexane. The filter cake is vacuum dried at 30℃ for 28h to obtain 18.7g of rod-shaped valrubicin with a yield of 93.5%.
[0033] Example 3
[0034] Take 20g of crude valrubicin, dissolve it in 100mL of 1,4-dioxane, slowly add 250mL of mixed solvent (30mL of isopropyl ether + 220mL of n-pentane), stir at low speed for 4h, and crystallize. Filter, wash the filter cake with 150mL of n-pentane. The filter cake is vacuum dried at 35°C for 25h to obtain 18.5g of rod-shaped valrubicin with a yield of 92.5%.
[0035] Example 4
[0036] Take 20g of crude valrubicin, dissolve it in 160mL of isopropyl ether, slowly add 320mL of mixed solvent (100mL of tert-butyl methyl ether + 220mL of n-pentane), stir at low speed for 5h, and crystallize. Filter, wash the filter cake with 240mL of n-pentane. The filter cake is vacuum dried at 35°C for 25h to obtain 18.6g of rod-shaped valrubicin with a yield of 93%.
[0037] Example 5
[0038] Take 20g of crude valrubicin, dissolve it in 100mL of tetrahydrofuran, slowly add 400mL of mixed solvent (100mL of methyl tert-butyl ether + 300mL of n-hexane), stir at low speed for 4h, and crystallize. Filter, and wash 300mL of the filter cake three times with n-hexane. The filter cake is vacuum dried at 40°C for 25h to obtain 18.8g of rod-shaped valrubicin with a yield of 94%.
[0039] Example 6
[0040] Take 20g of crude valrubicin, dissolve it in 160mL of tetrahydrofuran, slowly add 320mL of mixed solvent (100mL of isopropyl ether + 220mL of n-pentane), stir at low speed for 2h, and crystallize. Filter, wash the filter cake with 200mL of n-pentane. The filter cake is vacuum dried at 35°C for 25h to obtain 18.6g of rod-shaped valrubicin with a yield of 93%.
[0041] Example 7
[0042] Take 20g of crude valrubicin, dissolve it in 160mL of 1,4-dioxane, slowly add 320mL of mixed solvent (100mL of ether + 220mL of n-pentane), stir at low speed for 5h, and crystallize. Filter, wash the filter cake with 320mL of n-pentane. The filter cake is vacuum dried at 35°C for 25h to obtain 18.6g of rod-shaped valrubicin with a yield of 93%.
[0043] Example 8
[0044] Take 20g of crude valrubicin, dissolve it in 120mL of 1,4-dioxane, slowly add 320mL of mixed solvent (100mL of isopropyl ether + 220mL of n-hexane), stir at low speed for 3h, and crystallize. Filter, wash the filter cake with 240mL of n-hexane. The filter cake is vacuum dried at 35°C for 25h to obtain 18.6g of rod-shaped valrubicin with a yield of 93%.
[0045] Example 9
[0046] Take 20g of crude valrubicin, dissolve it in 100mL of isopropyl ether, slowly add 320mL of mixed solvent (100mL of isopropyl ether + 220mL of n-pentane), stir at low speed for 2.5h, and crystallize. Filter, wash the filter cake with 240mL of n-pentane. The filter cake is vacuum dried at 35°C for 25h to obtain 18.6g of rod-shaped valrubicin with a yield of 93%.
[0047] The samples prepared in Examples 2-9 have the same appearance as the sample in Example 1 under a microscope and have the same or similar XRPD patterns, indicating that the samples in Examples 2 to 9 and the sample in Example 1 are of the same crystal form.
[0048] The commercially available amorphous valrubicin powder and the rod-shaped valrubicin obtained in Example 1 were subjected to accelerated stability comparison: the two samples were placed in an environment of 50° C. with their openings opened, and samples were taken for testing after 10 days. The results are shown in the following table:
[0049]
[0050] The results in the above table show that the degradation product content of the rod-shaped crystalline solid obtained by this method is much lower than that of the amorphous powder, indicating that the obtained rod-shaped crystalline solid is more stable than amorphous valrubicin. This crystalline valrubicin has good stability under high temperature and air exposure, which is conducive to storage.
Claims
1. A method for preparing crystalline valrubicin, characterized in that: The following steps are involved: (1) Take crude valrubicin and dissolve it in an ether solvent; (2) adding a mixed solvent of small molecular ethers and alkanes to the dissolved crude product, and then stirring at a low speed for 0.5-10 hours to crystallize; the volume of the mixed solvent is 1-15 times the volume of the solvent; (3) filtering, washing with an alkane solvent, and vacuum drying at 0-60° C. for 1-50 h to obtain crystalline valrubicin; The ratio of the crude valrubicin to the ether solvent in step (1) is 1 g: (1-15) ml; The ether solvent in step (1) is one or more of diethyl ether, isopropyl ether, propyl ether, butyl ether, isobutyl ether, methyl tert-butyl ether, ethyl tert-butyl ether, tetrahydrofuran, and 1,4-dioxane; In step (2), the volume ratio of the small molecule ether solvent to the alkane solvent is 1:(0.1-20); The small molecular weight ether in step (2) is one or more of diethyl ether, tert-butyl methyl ether, dibutyl ether, isobutyl ether, isopropyl ether, tetrahydrofuran, and 1,4-dioxane; The alkane solvent in step (2) and step (3) is one or more of n-hexane, cyclohexane, n-pentane, isopentane, cyclopentane, n-heptane and petroleum ether; The volume of the alkane solvent used in step (3) is 1-5 times the volume of the solvent medium; The X-ray diffraction pattern of the crystalline form of valrubicin has characteristic peaks at the following 2θ angles: 6.7±0.2°, 7.4±0.2°, 9.9±0.2°, 16.8±0.2°, 17.2±0.2°, 20.9±0.2°, and 22.8±0.2°.
2. The method for preparing a crystalline form of valrubicin according to claim 1, characterized in that: The valrubicin obtained in step (3) is a rod-shaped crystal.
